MannKind Corporation announced a $50 million private placement led by Frazier Life Sciences, selling common stock and pre-funded warrants to institutional investors. The funds will support general corporate purposes, including a $45 million payment linked to the recent FDA approval of their drug Furoscix ReadyFlow™, an autoinjector for treating edema in heart failure and chronic kidney disease. The financing is expected to close around July 24, 2026, and MannKind plans to register the resale of these securities with the SEC. This capital raise aims to strengthen MannKind's position as it advances treatments for cardiometabolic and orphan lung diseases.
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
Across Protocol has advised users to avoid its app and refrain from connecting wallets or signing transactions due to a potential security incident involving its domain. Users have reported significant losses, including $9,000 in USDC and over 7,000 ...
The number of XRP addresses holding at least 10,000 tokens increased by 16,815 over nine months, reaching about 343,500 addresses, a 5.15% rise, even as XRP's price fell approximately 30% in seven weeks. Addresses holding one million or more XRP hit ...
Nvidia Corporation continues to be a compelling Buy despite recent share price declines and an ongoing investigation involving its CEO. The demand for Nvidia's chips remains strong, fueled by capital expenditure growth from hyperscalers and robust cl...
